Hiroaki Hisakawa
University of Tokyo
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hiroaki Hisakawa.
Journal of Clinical Investigation | 2000
Takahiro Ueda; Kohichiro Tsuji; Hiroshi Yoshino; Yasuhiro Ebihara; Hiroshi Yagasaki; Hiroaki Hisakawa; Tetsuo Mitsui; Atsushi Manabe; Ryuhei Tanaka; Kimio Kobayashi; Mamoru Ito; Kiyoshi Yasukawa; Tatsutoshi Nakahata
Here, we demonstrate a significant ex vivo expansion of human hematopoietic stem cells capable of repopulating in NOD/SCID mice. Using a combination of stem cell factor (SCF), Flk2/Flt3 ligand (FL), thrombopoietin (TPO), and a complex of IL-6 and soluble IL-6 receptor (IL-6/sIL-6R), we cultured cord blood CD34(+) cells for 7 days and transplanted these cells into NOD/SCID mice. Bone marrow engraftment was judged successful when recipient animals contained measurable numbers of human CD45(+) cells 10-12 weeks after transplantation. When cells were cultured with SCF+FL+TPO+IL-6/sIL-6R, 13 of 16 recipients were successfully engrafted, and CD45(+) cells represented 11.5% of bone marrow cells in engrafted recipients. Cells cultured with a subset of these factors were less efficiently engrafted, both as measured by frequency of successful transplantations and prevalence of CD45(+) cells. In animals receiving cells cultured with all 4 factors, human CD45(+) cells represented various lineages, including a large number of CD34(+) cells. The proportion of CD45(+) cells in recipient marrow was 10 times higher in animals receiving these cultured cells than in those receiving comparable numbers of fresh CD34(+) cells, and the expansion rate was estimated at 4.2-fold by a limiting dilution method. Addition of IL-3 to the cytokine combination abrogated the repopulating ability of the expanded cells. The present study may provide a novel culture method for the expansion of human transplantable hematopoietic stem cells suitable for clinical applications.
Bone Marrow Transplantation | 2000
Takefumi Ishii; Atsushi Manabe; Yasuhiro Ebihara; Takahiro Ueda; Hiroshi Yoshino; Tetsuo Mitsui; Hiroaki Hisakawa; Hiroshi Yagasaki; Akira Kikuchi; T Yoshimasu; Ryuhei Tanaka; Tsuneo A. Takahashi; Atsuko Masunaga; Sugita Ki; Tatsutoshi Nakahata; Shigetaka Asano; Kohichiro Tsuji
We report a 13-year-old boy who developed dyspnea at rest 1 year after the occurrence of cGVHD following an allogeneic bone marrow transplant (BMT). Pulmonary function data, imaging studies, lung biopsy, and bronchoalveolar lavage were consistent with the diagnosis of bronchiolitis obliterans organizing pneumonia (BOOP). Although reports suggest that oral methylprednisolone or methylprednisolone pulse therapies improve BOOP after BMT, we treated our patient with a combination of oral prednisolone (1 mg/kg) and low dose erythromycin (10 mg/kg) to avoid the side-effects of high-dose steroids. With this therapy, our patient showed clinical and radiological improvements within 1 week. The steroids were tapered off 12 months later and erythromycin was given for 14 months. We conclude that therapy consisting of a combination of oral prednisolone and low-dose erythromycin for BOOP after BMT may minimize the dose and duration of steroid use. Bone Marrow Transplantation (2000) 26, 907–910.
Bone Marrow Transplantation | 2001
T Yoshimasu; Ryuhei Tanaka; S Suenobu; Hiroshi Yagasaki; Hiroshi Yoshino; Takahiro Ueda; Hiroaki Hisakawa; Takefumi Ishii; T Mitsui; Yasuhiro Ebihara; Atsushi Manabe; T Iseki; Taira Maekawa; Tatsutoshi Nakahata; Shigetaka Asano; Kohichiro Tsuji
We describe here the case of an 8-year-old girl with Fanconi anemia (FA) whose hematopoiesis was successfully restored by unrelated umbilical cord blood (UCB) transplantation. The patient became resistant to androgen therapy, and developed intracranial hemorrhage and dyserythropoiesis. Her hematopoietic recovery after the transplantation was excellent and a complete chimerism has been durably maintained. UCB should be considered as a stem cell source for transplantation when a patient with FA does not have an HLA-identical unaffected sibling donor. Bone Marrow Transplantation (2001) 27, 767–769.
Blood | 1999
Shinsaku Imashuku; Shigeyoshi Hibi; Toshio Ohara; Asayuki Iwai; Masahiro Sako; Masahiko Kato; Hirokazu Arakawa; Manabu Sotomatsu; Satoshi Kataoka; Keiko Asami; Daijiro Hasegawa; Yoshiyuki Kosaka; Kimihiko Sano; Noboru Igarashi; Keiko Maruhashi; Ryouji Ichimi; Hajime Kawasaki; Naoko Maeda; Akihiko Tanizawa; Koji Arai; Takanori Abe; Hiroaki Hisakawa; Hidemasa Miyashita; Jan-Inge Henter
Blood | 2001
Sahoko Matsuoka; Kohichiro Tsuji; Hiroaki Hisakawa; Ming Jiang Xu; Yasuhiro Ebihara; Takefumi Ishii; Daisuke Sugiyama; Atsushi Manabe; Ryuhei Tanaka; Yasuo Ikeda; Shigetaka Asano; Tatsutoshi Nakahata
International Journal of Hematology | 2000
Takahiro Ueda; Atsushi Manabe; Akira Kikuchi; Hiroshi Yoshino; Yasuhiro Ebihara; Takefumi Ishii; Hiroshi Yagasaki; Tetsuo Mitsui; Hiroaki Hisakawa; Atsuko Masunaga; Kohichiro Tsuji; Tatsutoshi Nakahata
Blood | 2001
Hiroaki Hisakawa; Daisuke Sugiyama; Ichiko Nishijima; Mingjiang Xu; Hong Wu; Kazuki Nakao; Sumiko Watanabe; Motoya Katsuki; Shigetaka Asano; Ken-ichi Arai; Tatsutoshi Nakahata; Kohichiro Tsuji
Archive | 2016
Shinsaku Imashuku; Shigeyoshi Hibi; Toshio Ohara; Asayuki Iwai; Masahiro Sako; Masahiko Kato; Hirokazu Arakawa; Manabu Sotomatsu; Satoshi Kataoka; Keiko Asami; Daijiro Hasegawa; Yoshiyuki Kosaka; Kimihiko Sano; Noboru Igarashi; Keiko Maruhashi; Ryouji Ichimi; Hajime Kawasaki; Naoko Maeda; Akihiko Tanizawa; Koji Arai; Takanori Abe; Hiroaki Hisakawa; Hidemasa Miyashita; Jan-Inge Henter
Archive | 2013
Daisuke Sugiyama; Atsushi Manabe; Ryuhei Tanaka; Yasuo Ikeda; Shigetaka Asano; Sahoko Matsuoka; Kohichiro Tsuji; Hiroaki Hisakawa; Ming Jiang Xu; Yasuhiro Ebihara; Takefumi Ishii
Archive | 2013
Shigetaka Asano; Ken-Ichi Arai; Tatsutoshi Nakahata; Kohichiro Tsuji; Hiroaki Hisakawa; Daisuke Sugiyama; Ichiko Nishijima; Ming Jiang Xu; Kazuki Nakao